Related Experiment Video
Updated: Jul 11, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
[Pemetrexed development in oncology].
Loïc Chaigneau1, Christian Villanueva, Antoine Thierry-Vuillemin
1Service d'oncologie médicale, centre hospitalier universitaire Jean-Minjoz, 25000 Besançon. lchaigneau@chu-besancon.fr
Pemetrexed disodium (Alimta) is a novel antifolate chemotherapy drug effective against various cancers. Its efficacy and tolerance are linked to vitamin levels, with established use in mesothelioma and non-small cell lung cancer.
Area of Science:
- Oncology
- Pharmacology
Context:
- Pemetrexed disodium (Alimta) is a unique antifolate agent.
- It targets both purine and pyrimidine synthesis pathways.
- Previous antifolates like methotrexate and fluorouracil demonstrated effectiveness.
Purpose:
- To evaluate the therapeutic efficacy and tolerance of pemetrexed disodium in various cancers.
- To understand the relationship between vitamin deficiencies and pemetrexed-induced toxicities.
Summary:
- Pemetrexed disodium exhibits significant activity across numerous tumor types.
- Tolerance profiles vary, with toxicities linked to vitamin deficiencies identified in 2001.
- Randomized studies confirmed its utility in malignant pleural mesothelioma and non-small cell lung cancer.
Impact:
- Pemetrexed disodium is now a recorded treatment for specific cancers.
- Further development is ongoing for other cancers, including head and neck, breast, and digestive/urinary tract cancers.
- Optimizing dosage, administration, and combinations holds promise for pemetrexed's future in chemotherapy.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Treatment Resistent Cancers
Treatment Resistant Cancers
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...